

Mohamad Mohty

Mohamad Mohty is full Professor of Hematology and head of the Hematology and cellular therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France).

Professor Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK.

Professor Mohty's is also head of a translational research team (INSERM team N°7) at the Saint-Antoine Research centre in Paris and his research is focused on the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially **the impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs and hypomethylating agents.**

He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and different aspects of therapy of acute leukemia and multiple myeloma.

Professor Mohty is past-president **of the *European Society for Blood and Marrow Transplantation (EBMT)*, and the current chairman of the Acute Leukemia Working Party of EBMT.** He is also the founder and chairman of the ***“International Academy for Clinical Hematology*** (IACH; <http://clinical-hematology.org/>). He serves on the board of the EBMT, and the ***“Intergruppe Francophone du Myelome” (IFM)***. He is a member of the American Society of Hematology (ASH), American Society for Clinical Oncology (ASCO), American Society for Blood and Marrow Transplantation, European Hematology Association (EHA), and EBMT.

Professor Mohty has published more than 600 peer-reviewed articles (<https://www.ncbi.nlm.nih.gov/pubmed/?term=MOHTY+M>) in the field of stem cell transplantation, leukemia and myeloma, in different hematology and immunology journals.

He also serves as **Editor-in-Chief of the journals *Bone Marrow Transplantation* and *Clinical Hematology International***, as Associate Editor for *Leukemia*, *European Journal of Haematology* and *Blood Cancer Journal*, as member of the editorial board of *Haematologica*, and as a regular reviewer in different immunology, hematology, and cancer journals such as the *New Engl. J Med*, *Blood*, *J Clin Oncol*, *The Lancet*, *Lancet Oncology*, *Lancet Haematology*, *Nature Reviews*, etc.